secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001125345-23-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports 2022 net loss of $119.8M; cash runway extended through 2025 via $250M non-dilutive funding
--------------------------------------------------------------------------------

- Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).
- Cash $154.3M at Dec 2022; plus $100M from DRI royalty sale; runway through 2025.
- TAMARACK trial modified: removed control arm; clinical update expected in 2024.
- Lorigerlimab mCRPC data: 28.6% PSA50, 25.7% confirmed partial responses.
- TZIELD approval milestone: two $15M payments received; two due by Sept 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/0001125345-23-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/mgnx-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer